ATC Group: A16AA06 Betaine

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of A16AA06 in the ATC hierarchy

Level	Code	Title
`1`	A	Alimentary tract and metabolism
`2`	A16	Other alimentary tract and metabolism products
`3`	A16A	Other alimentary tract and metabolism products
`4`	A16AA	Amino acids and derivatives
`5`	A16AA06	Betaine

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Code	Route	Amount	Notes
ORAL	Oral	6 g

Active ingredients in A16AA06

Active Ingredient
Betaine
Betaine anhydrous was shown to lower plasma homocysteine levels in the three types of homocystinuria, i.e. CBS deficiency; MTHFR deficiency and cbl defect. The extent of this effect was dependent on the absolute degree of hyperhomocysteinemia, being higher in severe hyperhomocysteinemia. Betaine anhydrous acts as a methyl group donor in the remethylation of homocysteine to methionine in patients with homocystinuria.

Related product monographs

Document	Type	Information Source
AMVERSIO Oral powder	MPI, EU: SmPC	European Medicines Agency (EU)
CYSTADANE Oral powder	MPI, EU: SmPC	European Medicines Agency (EU)
CYSTADANE Powder for oral solution	MPI, US: SPL/PLR	FDA, National Drug Code (US)